

Bringing Cuba's lung cancer vaccine to the States

August 27 2015, by Kelvin Lee

Amid a historic normalizing of relations between the United States and Cuba, a potentially game-changing step was recently taken in the field of lung cancer research.

When thinking about cutting-edge scientific innovation, Cuba may not immediately come to mind. Relations between the United States and the small island nation to the south of Florida grew tense during the height of the Cold War, and the two countries have been locked in a trade embargo since 1962. Only very recently have diplomatic relations thawed, opening the door for collaboration.

A mystery to generations of Americans, Cuba is often thought of as being stuck in a bygone era. Having made multiple trips to Cuba over the last three years, I can tell you that is not the case.

Cuba's high-quality biotech sector is thriving, led in part by the Center for Molecular Immunology (CIM) in Havana. I visited the CIM in April 2015 as part of a group that included Roswell Park Cancer Institute's (RPCI) President and CEO Candace Johnson, PhD, and New York Governor Andrew Cuomo. Following face-to-face meetings with CIM representatives and researchers, an agreement was finalized to bring their lung cancer vaccine, CimaVax, to RPCI and the United States for clinical testing and U.S. Food and Drug Administration (FDA) inspection.

Potential Impact

So, what is CimaVax? First and foremost, let me immediately clear up a potential misconception – CimaVax, in its current form, is not the type of vaccine that would be administered to children to prevent them from some day getting lung cancer.

Rather, CimaVax is intended for [lung cancer patients](#) and for those at high risk for the disease, including smokers and patients who may have had lung cancer removed surgically. Unlike other immunotherapies, CimaVax does not target cancer directly and it is not personalized. Rather, the vaccine targets a growth factor (EGF) necessary for the cancer to survive. By targeting and effectively depleting this [growth factor](#), the cancer starves and its progress slows, prolonging patients' lives.

To date, CimaVax has been administered to 5,000 patients across the world, including 1,000 Cubans. Expansive clinical trials have been underway for some time now, with published data showing prolonged life (especially in patients

Citation: Bringing Cuba's lung cancer vaccine to the States (2015, August 27) retrieved 23 November 2024 from

<https://medicalxpress.com/news/2015-08-cuba-lung-cancer-vaccine-states.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.